Walgreens has been sued by Arkansas Attorney General Leslie Rutledge, and the case was filed earlier this week. In her filing, she claimed that the pharmacy chain company played a big part in making the opioid crisis situation in the state worse.
Rutledge accused Walgreens of rendering a large number of orders for painkillers, and most of them are suspicious. The lawyer said that this is a violation of Arkansas’ Deceptive Trade Practices Act.
The lawsuit against Walgreens
The lawsuit was filed in Pulaski County Court, and it was stated that the pharmacy did not do enough to make sure that the prescriptions are legitimate and not questionable. It was said that because of Walgreens' failure to monitor the orders, large amounts of the regulated drug were distributed in Arkansas, as per Arkansas Democrat Gazelle.
"Walgreens has a legal responsibility to report suspicious orders and suspicious prescriptions," the attorney general said. "By failing to do so they enabled the black market of prescription drugs to increase dramatically, thus leading to more, greater addiction and more lives lost in the state of Arkansas."
As stated in the lawsuit, from 2006 to 2014, Walgreens fulfilled orders of over 142 million dosages of oxycodone and hydrocodone in the state. Rutledge said that this big amount should have alerted the company to the fact that suspicious orders were being placed.
It was added that such quantities that were distributed in Arkansas far exceeded the normal amount that could be consumed for medical legit purposes. “Walgreens failed to report and halt those orders and instead increased the number of pills distributed,” the statement from the suit reads.
With the filing, the state is seeking a directive that will force Walgreens to act responsibly and comply with federal and state laws. It is also seeking appropriate civil penalties for every violation that the company may have committed against the state’s consumer protection laws.
Walgreens denies the allegations
Walgreens refuted the accusations and stated that it never produced or marketed opioids. The company’s spokesperson further told FOX Business that they never sold the said drug to pain clinics, online pharmacies, and 'pill mills' that worsened the opioid crisis.
"Prior to 2014, we delivered opioids only to our own pharmacies, and the only place we ever sold FDA-approved opioid medications was at the pharmacy counter when presented with valid prescriptions written by DEA-licensed physicians for legitimate medical needs," the firm’s spokesperson said.
Finally, he added that the company’s pharmacists always evaluate and take the law into consideration before deciding whether to fill a prescription for controlled substances.


TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 



